Gail Dutton

Gail Dutton

Gail Dutton has covered the biotech industry since soon after its inception, focusing on the intersection of business and science.

ARTICLES BY GAIL DUTTON

  • Pharma Embraces The Cloud ... Cautiously
    Pharma Embraces The Cloud ... Cautiously

    Pharmaceutical companies that have, until recently, eschewed cloud computing are migrating applications into that environment. Adoption began gradually, first with functions that aren’t mission-critical. After a few years’ experience, they’re still cautious, seeking to adopt the cloud strategically while minimizing risks.

  • Pharma Field Trips: Is Hosting The FDA A Good Idea?
    Pharma Field Trips: Is Hosting The FDA A Good Idea?

    Inviting FDA scientists into your manufacturing facility or laboratory for one or two days may feel unsettling, but it can be rewarding when the visits are designed to bring FDA scientists up to speed on real-world issues and new technologies.

  • Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules
    Most U.S. Pharmas Ignore Cuba, Despite Relaxed Rules

    Two American organizations go on the record to discuss their work with Cuban researchers and their efforts to bring innovative research involving cancer vaccines and levels of consciousness (e.g., comas, brain death) to American patients.

  • Cell Therapy Regulations Approach Their Inflection Point
    Cell Therapy Regulations Approach Their Inflection Point

    The need for discussions regarding guidelines for the development of therapeutics made from human cells, tissues, and cell- and tissue-based products has been building for a long time.

  • Biotech Bounces Back: A Tale Of Two Companies
    Biotech Bounces Back: A Tale Of Two Companies

    The fascinating stories of how Akari Therapeutics and Oncolytics Biotech each faced devastating challenges in their evolution and ultimately reinvented themselves.

  • The Common Elements Of Top-Performing Pharmas
    The Common Elements Of Top-Performing Pharmas

    Top-performing pharmaceutical companies aren’t like their peers. The top six companies have each found their own “secret sauce” that, according to a recent Accenture report, helps them dominate their markets and boost profit margins far beyond those of their peers.

  • Is Your Board Capable Of Overseeing IT?
    Is Your Board Capable Of Overseeing IT?

    Life sciences companies are at a crossroads, although they may not recognize it. Information technology is transitioning from a tool to a strategic element that contributes to business success. Most boards, however, are ill-equipped to guide this transformation.

  • The Changing Role Of The Pharma CIO
    The Changing Role Of The Pharma CIO

    "Companies that recognize the opportunities associated with digital transformation are more likely to bring in fresh blood,” Murray Aitken, executive director, IMS Institute, says.

  • Patient Services Offer Competitive Advantage For Pharma
    Patient Services Offer Competitive Advantage For Pharma

    According to “The Patient is IN: Pharma’s Growing Opportunity in Patient Services,” a recent Accenture survey of 200 patient services executives in the U.S. and Europe, 9 of the 10 most common patient services deliver above-average business impact.

  • The Business Benefits Of Revisiting Abandoned Therapies
    The Business Benefits Of Revisiting Abandoned Therapies

    DelMar Pharmaceuticals’ small molecule oncology program began with a short list of compounds that advanced to Phase 2 at the NIH but were never commercialized. By developing drugs that were in Phase 2 trials many years ago rather than creating entirely new drugs, DelMar has the benefit of beginning a program with a large body of knowledge.

More From Gail Dutton